← All trials
NCT03372694
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2016
- Primary completion
- Sep 30, 2019
- Completion date
- Dec 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 354
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai University of Traditional Chinese MedicineLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Fudan UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Shanghai University of Traditional Chinese MedicineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.